AU2018320946B2 - Amantadine compositions, preparations thereof, and methods of use - Google Patents

Amantadine compositions, preparations thereof, and methods of use Download PDF

Info

Publication number
AU2018320946B2
AU2018320946B2 AU2018320946A AU2018320946A AU2018320946B2 AU 2018320946 B2 AU2018320946 B2 AU 2018320946B2 AU 2018320946 A AU2018320946 A AU 2018320946A AU 2018320946 A AU2018320946 A AU 2018320946A AU 2018320946 B2 AU2018320946 B2 AU 2018320946B2
Authority
AU
Australia
Prior art keywords
amantadine
pharmaceutical composition
subject
hours
oral pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018320946A
Other languages
English (en)
Other versions
AU2018320946A1 (en
Inventor
Timothy J. Fultz
Sangita Ghosh
Natalie MCCLURE
Gregory T. Went
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adamas Pharma LLC
Original Assignee
Adamas Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamas Pharma LLC filed Critical Adamas Pharma LLC
Publication of AU2018320946A1 publication Critical patent/AU2018320946A1/en
Application granted granted Critical
Publication of AU2018320946B2 publication Critical patent/AU2018320946B2/en
Priority to AU2024205201A priority Critical patent/AU2024205201A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2018320946A 2017-08-24 2018-08-23 Amantadine compositions, preparations thereof, and methods of use Active AU2018320946B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024205201A AU2024205201A1 (en) 2017-08-24 2024-07-30 Amantadine compositions, preparations thereof, and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549921P 2017-08-24 2017-08-24
US62/549,921 2017-08-24
PCT/US2018/047754 WO2019040748A1 (en) 2017-08-24 2018-08-23 AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024205201A Division AU2024205201A1 (en) 2017-08-24 2024-07-30 Amantadine compositions, preparations thereof, and methods of use

Publications (2)

Publication Number Publication Date
AU2018320946A1 AU2018320946A1 (en) 2020-04-16
AU2018320946B2 true AU2018320946B2 (en) 2024-05-02

Family

ID=65439620

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018320946A Active AU2018320946B2 (en) 2017-08-24 2018-08-23 Amantadine compositions, preparations thereof, and methods of use
AU2024205201A Pending AU2024205201A1 (en) 2017-08-24 2024-07-30 Amantadine compositions, preparations thereof, and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024205201A Pending AU2024205201A1 (en) 2017-08-24 2024-07-30 Amantadine compositions, preparations thereof, and methods of use

Country Status (10)

Country Link
US (3) US11077073B2 (enExample)
EP (1) EP3672581A4 (enExample)
JP (3) JP2020531543A (enExample)
CN (2) CN111372578A (enExample)
AU (2) AU2018320946B2 (enExample)
BR (1) BR112020003375A2 (enExample)
CA (1) CA3072764A1 (enExample)
IL (1) IL272834B2 (enExample)
MX (2) MX2020002078A (enExample)
WO (1) WO2019040748A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
MX2020002078A (es) 2017-08-24 2020-09-21 Adamas Pharma Llc Composiciones de amantadina, preparaciones de estas y métodos de uso.
US11441653B1 (en) 2021-05-20 2022-09-13 Dana Automotive Systems Group, Llc Integrated gearbox in electric motor systems

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006058059A2 (en) * 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
US20100221328A1 (en) * 2008-12-31 2010-09-02 Wertz Christian F Sustained-release formulations
US20110189273A1 (en) * 2009-12-02 2011-08-04 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2014204933A1 (en) * 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
EP2965753A1 (en) * 2004-12-03 2016-01-13 Osmotica Kereskedelmi És Szolgáltató Kft Osmotic device containing amantadine and an osmotic salt

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JP2623099B2 (ja) 1987-11-06 1997-06-25 株式会社ニフコ スライダの引込み装置
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
WO1997045091A2 (en) 1996-05-31 1997-12-04 Euro-Celtique, S.A. Sustained release oxycodone formulations with no fed/fast effect
US5849800A (en) 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020071863A1 (en) 1999-12-09 2002-06-13 Dong Liang C. Antiviral medication
EP1368000A4 (en) 2001-03-13 2004-12-01 Penwest Pharmaceuticals Co CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID
US20060198815A1 (en) 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
DE10129265A1 (de) 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US20030158154A1 (en) 2001-07-17 2003-08-21 Moshe Fleshner-Barak Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20030045577A1 (en) 2001-08-15 2003-03-06 Madhat Maher N. Method for preventing infectious respiratory diseases
AU2003298514A1 (en) 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
AU2003227516B2 (en) 2002-05-31 2008-03-20 H. Lundbeck A/S A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
WO2004012741A1 (en) 2002-07-29 2004-02-12 Glaxo Group Limited Sustained release formulations comprising lamotrigine
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
AU2003274353B2 (en) 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060024366A1 (en) 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040224020A1 (en) 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AR043467A1 (es) 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
WO2005027843A2 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
MXPA06003100A (es) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis de liberacion retardada.
ATE411015T1 (de) 2003-10-22 2008-10-15 Merz Pharma Gmbh & Co Kgaa Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7211275B2 (en) 2004-01-16 2007-05-01 Massachusetts Institute Of Technology Composite materials for controlled release of water soluble products
CA2554959A1 (en) 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
AU2005215767A1 (en) 2004-02-13 2005-09-01 Adamas Pharmaceuticals, Inc. Combination of an NMDA receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other CNS disorders
ATE454140T1 (de) 2004-02-18 2010-01-15 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
TW200531680A (en) 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
US8039009B2 (en) 2004-06-17 2011-10-18 Forest Laboratories Holdings Limited Modified release formulations of memantine oral dosage forms
JP2006079138A (ja) 2004-09-07 2006-03-23 Ricoh Co Ltd ステータス取得方法、プリンタドライバ及び情報処理装置
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20190008799A1 (en) 2004-11-23 2019-01-10 Adamas Pharma, Llc Composition for administering an nmda receptor antagonist to a subject
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20190328684A1 (en) 2004-11-24 2019-10-31 Adamas Pharma, Llc Composition and method for treating neurological disease
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
US8252331B2 (en) 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
WO2006089066A1 (en) 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Combinations therapy for treatment of demyelinating conditions
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
WO2007036952A2 (en) 2005-07-01 2007-04-05 Rubicon Research Pvt Ltd. Novel sustained release dosage form
EP1942875B1 (en) 2005-08-24 2015-08-12 Rubicon Research Private Limited Controlled release formulation
US20070104778A1 (en) 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
MX2009002235A (es) 2006-08-30 2009-03-13 Jagotec Ag Formulaciones de dosis oral, solidas, de liberacion controlada que comprenden nisoldipina.
EP1961414A1 (en) 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. A controlled release composition comprising a recombinant gelatin
EP2129683A4 (en) * 2007-02-26 2011-01-05 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
EP2322168A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
EP1987815A1 (en) 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
MX2009013019A (es) 2007-05-30 2010-04-01 Neos Therapeutics Lp Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica.
US8247438B2 (en) * 2008-02-27 2012-08-21 Neuropill, Inc. Methods for treating schizophrenia
US20110142905A1 (en) 2008-08-14 2011-06-16 Bioneer A/S Coated tablets with remaining degradation surface over the time
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
HUE032817T2 (en) 2009-03-18 2017-11-28 Evonik Roehm Gmbh Regulated release pharmaceutical composition comprising a coating containing neutral vinyl polymers and excipients and resistant to the influence of ethanol
EP2411083A4 (en) 2009-03-23 2013-11-13 Micell Technologies Inc MEDICAL ACTIVE COMPOSITION DEVICE
EP2413898A1 (en) 2009-04-03 2012-02-08 Coating Place, Inc. Modified-release pharmaceutical drug composition
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
US8895662B2 (en) 2010-12-31 2014-11-25 Eternal Chemical Co., Ltd. Curable composition and method for manufacturing the same
US20130236544A1 (en) * 2012-03-08 2013-09-12 Dr. Reddy's Laboratories Ltd. Stable pharmaceutical compositions of fesoterodine
CN107205950B (zh) * 2014-11-04 2021-06-04 阿达玛斯药物有限责任公司 金刚烷胺组合物的施用方法
GB201516037D0 (en) 2015-09-10 2015-10-28 Agco Int Gmbh Vehicle axel assembly
MX2020002078A (es) 2017-08-24 2020-09-21 Adamas Pharma Llc Composiciones de amantadina, preparaciones de estas y métodos de uso.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006058059A2 (en) * 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
EP2965753A1 (en) * 2004-12-03 2016-01-13 Osmotica Kereskedelmi És Szolgáltató Kft Osmotic device containing amantadine and an osmotic salt
US20100221328A1 (en) * 2008-12-31 2010-09-02 Wertz Christian F Sustained-release formulations
US20110189273A1 (en) * 2009-12-02 2011-08-04 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US20170151190A1 (en) * 2009-12-02 2017-06-01 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2014204933A1 (en) * 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use

Also Published As

Publication number Publication date
IL272834B1 (en) 2024-04-01
CA3072764A1 (en) 2019-02-28
US11065213B2 (en) 2021-07-20
US20190262285A1 (en) 2019-08-29
BR112020003375A2 (pt) 2020-08-25
US20200069614A1 (en) 2020-03-05
JP2020531543A (ja) 2020-11-05
IL272834B2 (en) 2024-08-01
AU2018320946A1 (en) 2020-04-16
CN117860718A (zh) 2024-04-12
WO2019040748A1 (en) 2019-02-28
EP3672581A1 (en) 2020-07-01
JP2023009251A (ja) 2023-01-19
US12233033B2 (en) 2025-02-25
US11077073B2 (en) 2021-08-03
AU2024205201A1 (en) 2024-08-15
EP3672581A4 (en) 2021-05-19
IL272834A (en) 2020-04-30
JP2024159885A (ja) 2024-11-08
US20220117914A1 (en) 2022-04-21
MX2020002078A (es) 2020-09-21
CN111372578A (zh) 2020-07-03
MX2023012198A (es) 2023-10-25

Similar Documents

Publication Publication Date Title
US11197835B2 (en) Method of administering amantadine prior to a sleep period
US11903908B2 (en) Methods of administering amantadine
AU2024205201A1 (en) Amantadine compositions, preparations thereof, and methods of use
AU2015202356B2 (en) Amantadine compositions and methods of use
HK1234346A1 (en) Amantadine compositions and methods of use
HK1234346A (en) Amantadine compositions and methods of use
HK1176818B (en) Amantadine compositions and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)